Novartis AG (NVS)
NYSE·Healthcare·Drug Manufacturers - General
$144.84
+0.45%
Mkt Cap $314.69B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 4, 2026 | $13.70B | $13.34B | -2.69% | $1.99 | $2.03 | +2.01% | — | — |
| Q4 2025 Oct 28, 2025 | $13.64B | $14.36B | +5.25% | $2.26 | $2.25 | -0.44% | — | — |
| Q3 2025 Jul 17, 2025 | $13.94B | $14.28B | +2.47% | $2.38 | $2.42 | +1.68% | — | — |
| Q2 2025 Apr 29, 2025 | $13.90B | $13.62B | -2.01% | $2.12 | $2.28 | +7.55% | — | — |
| Q1 2025 Jan 31, 2025 | $12.84B | $13.56B | +5.61% | $1.80 | $1.98 | +10.00% | — | — |
| Q4 2024 Oct 29, 2024 | $12.76B | $13.17B | +3.20% | $1.94 | $2.06 | +6.19% | — | — |
| Q3 2024 Jul 18, 2024 | $12.54B | $12.51B | -0.23% | $1.89 | $1.97 | +4.23% | — | — |
| Q2 2024 Apr 23, 2024 | $11.44B | $11.83B | +3.40% | $1.73 | $1.80 | +4.05% | — | — |
| Q1 2024 Jan 31, 2024 | $11.88B | $11.78B | -0.91% | $1.64 | $1.53 | -6.71% | — | — |
| Q4 2023 Oct 24, 2023 | $12.42B | $12.09B | -2.61% | $1.70 | $1.74 | +2.35% | — | — |
| Q3 2023 Jul 18, 2023 | $13.47B | $13.94B | +3.43% | $1.68 | $1.83 | +8.93% | — | — |
| Q2 2023 Apr 25, 2023 | $12.72B | $13.21B | +3.86% | $1.55 | $1.71 | +10.32% | — | — |
| Q1 2023 Feb 1, 2023 | $13.22B | $13.09B | -1.00% | $1.42 | $1.51 | +6.34% | — | — |
| Q4 2022 Oct 25, 2022 | $12.88B | $12.84B | -0.33% | $1.57 | $1.58 | +0.64% | — | — |
| Q3 2022 Jul 19, 2022 | $12.88B | $13.09B | +1.59% | $1.51 | $1.56 | +3.31% | — | — |
| Q2 2022 Apr 26, 2022 | $12.62B | $12.81B | +1.55% | $1.44 | $1.46 | +1.39% | — | — |
| Q1 2022 Feb 2, 2022 | $13.33B | $13.52B | +1.46% | $1.44 | $1.40 | -2.78% | — | — |
| Q4 2021 Oct 26, 2021 | $12.95B | $13.37B | +3.21% | $1.65 | $1.71 | +3.64% | — | — |
| Q3 2021 Jul 21, 2021 | $12.95B | $13.29B | +2.64% | $1.53 | $1.66 | +8.50% | — | — |
| Q2 2021 Apr 27, 2021 | $13.25B | $12.69B | -4.22% | $1.57 | $1.52 | -3.18% | — | — |